<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Lamininα2-deficient <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo> type 1A (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDC1A</z:e>) is a cureless disease associated with severe disability and shortened lifespan </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies have shown reduced <z:mp ids='MP_0003045'>fibrosis</z:mp> and restored skeletal muscle remodeling following treatment with <z:chebi fb="0" ids="6541">losartan</z:chebi>, an <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> type I receptor blocker </plain></SENT>
<SENT sid="2" pm="."><plain>We therefore evaluated the effect of <z:chebi fb="0" ids="6541">losartan</z:chebi> treatment in the dy(2J) /dy(2J) mouse model of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDC1A</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Homozygous dy(2J) /dy(2J) and control mice were treated with <z:chebi fb="0" ids="6541">losartan</z:chebi> or placebo for 12 weeks from 6 weeks of age </plain></SENT>
<SENT sid="4" pm="."><plain>Outcome measures included hindlimb and forelimb muscle strength by Grip Strength Meter and quantitative muscle <z:mp ids='MP_0003045'>fibrosis</z:mp> parameters </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="6541">Losartan</z:chebi>'s effects on transforming growth factor β (TGF-β) and <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase (MAPK) signaling pathways were evaluated with Western blotting, immunofluorescence, and cytokine measurements </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:chebi fb="0" ids="6541">Losartan</z:chebi> treatment was associated with significant impressive improvement in muscle strength and amelioration of <z:mp ids='MP_0003045'>fibrosis</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Administration of <z:chebi fb="0" ids="6541">losartan</z:chebi> inhibited TGF-β signaling pathway, resulting in decreased serum TGF-β1 level and reduced downstream phosphorylated (P) Smad2/3 proteins </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, <z:chebi fb="0" ids="6541">losartan</z:chebi> activated Smad7 protein, a key negative regulator of TGF-β signaling </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, <z:chebi fb="0" ids="6541">losartan</z:chebi> treatment inhibited the MAPK cascade as shown by decreased expression of P-p38 MAPK, P-c-jun-N-terminal kinase, and P-extracellular signal-regulated kinases 1 and 2 in the treated mice </plain></SENT>
<SENT sid="10" pm="."><plain>INTERPRETATION: <z:chebi fb="0" ids="6541">Losartan</z:chebi>, a commonly prescribed US Food and Drug Administration-approved medication for <z:hpo ids='HP_0000822'>hypertension</z:hpo>, demonstrated clinical improvement and amelioration of <z:mp ids='MP_0003045'>fibrosis</z:mp> in the dy(2J) /dy(2J) mouse model of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDC1A</z:e> via TGF-β and MAPK signaling pathways </plain></SENT>
<SENT sid="11" pm="."><plain>The results of this study support pursuing a clinical trial of <z:chebi fb="0" ids="6541">losartan</z:chebi> treatment in children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDC1A</z:e> </plain></SENT>
</text></document>